Our products speak for themselves in quality and performance. REQUEST A FREE SAMPLE

Recent Citations Utilizing Mirus Reagents for COVID Research

Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza
Authors: Timothy R. Abbott, Girija Dhamdhere, Yanxia Liu, et al.
Journal: Cell, Volume 181, Issue 4, 14 May 2020, Pages 865-876.e12
DOI: 10.1016/j.cell.2020.04.020
Link: https://www.sciencedirect.com/science/article/pii/S0092867420304839
Product Usage: TransIT®-LT1 Transfection Reagent was used for (1) transfection of crRNA pools targeting two SARS-COV-2 into human lung epithelial cells (A549 cells) and (2) SARS-COV-2 reporter lentivirus generation. This study demonstrates "a CRISPR-Cas13-based strategy, PAC-MAN (prophylactic antiviral CRISPR in human cells), for viral inhibition that can effectively degrade RNA from SARS-CoV-2 sequences and live influenza A virus (IAV) in human lung epithelial cells."

Distinct Inductions of and Responses to Type I and Type III Interferons Promote Infections in Two SARS-CoV-2 Isolates
Authors: Fu Hsin, Tai-Ling Chao, Yun-Rui Chan, et al.
Journal: bioRxiv – May 1, 2020
DOI: 10.1101/2020.04.30.071357
Link: https://www.biorxiv.org/content/10.1101/2020.04.30.071357v1.abstract
Product Usage: TransIT®-mRNA Transfection Kit was used to deliver total RNA isolated from either SARS-COV-2, Sendai virus or mock-infected Calu-3 cells into mouse embryonic fibroblasts (MEFs) in order to characterize the post-infection induction of and response to type I/III interferons.

Single-dose replicating RNA vaccine induces neutralizing antibodies against SARS-CoV-2 in nonhuman primates
Authors: Jesse H. Erasmus, Amit P. Khandhar, Alexandra C. Walls, et al.br /> Journal: bioRxiv – Posted May 28, 2020
DOI: 10.1101/2020.05.28.121640
Link: https://www.biorxiv.org/content/10.1101/2020.05.28.121640v1.abstract
Product Usage: TransIT®-mRNA Transfection Kit was used to deliver transcribed virus-derived replicon RNA molecules (including vaccine candidate repRNA-COV2S and control repRNA-GFP) to BHK cells for in vitro repRNA vaccine candidate qualification.

Human organs-on-chips as tools for repurposing approved drugs as potential influenza and COVID19 therapeutics in viral pandemics
Journal: bioRxiv – Posted April 15, 2020
DOI: 10.1101/2020.04.13.039917
Link: https://www.biorxiv.org/content/10.1101/2020.04.13.039917v2
Product Usage: TransIT-X2® Dynamic Delivery System was used to (1) produce SARS-CoV-2 spike pseudotyped HIV virions (SARS-CoV-2pp) and VSVG pseudotyped HIV virions (VSVpp) in HEK cells, and (2) to transfect serine protease & control plasmids into MDCK cells for analysis of HA cleavage by serine proteases in the presence or absence of nafamostat (an anticoagulant drug with potential antiviral effects).

Direct RNA nanopore sequencing of full-length coronavirus genomes provides novel insights into structural variants and enables modification analysis
Authors: Adrian Viehweger, Sebastian Krautwurst, Kevin Lamkiewicz, et al.
Journal: Genome Research (2019) 29:1545
DOI: 10.1101/gr.247064.118
Link: https://genome.cshlp.org/content/29/9/1545.short
Product Usage: TransIT®-mRNA Transfection Kit was used to deliver in vitro transcribed full length genomic RNAs (HCoV-229E, HCoV-229E_SL2-SARS-CoV, and HCoV-229E_SL2-BCoV) and in vitro transcribed HCoV-229E nucleocapsid protein mRNA to Huh7 cells.